

# Monitoring of Sales of Veterinary Antimicrobial Agents in Europe

Considerations from Industry

Valérie Thomas
Olivier Espeisse
IFAH-Europe
London 25th November 2009



#### **Plan**



- IFAH-Europe
- Reminder of previous meetings / papers
- Key principles
- How to collect data
- How to report data
- ATCvet code / DDD
- Case of feed additives
- Conclusion

## **IFAH-Europe**



#### <u>Updated market representation 2009</u>

#### IFAH-Europe represents:

- 90% of the European market in veterinary medicinal products (VMP)
- 15% of this value is generic VMPs
- 15 international companies as corporate members
- 18 national associations, representing ~300 local companies
- VMP market is 3% of the human pharma market

# **Key Elements for Consideration and Proposals (Slide presented at Marianske Lazne 20th May 2009)**



- All marketers to be involved!
- National approaches! may be the only way - versus central data generation
- Collection of context data! (e.g. animal production numbers, disease prevalence)
- Simple and pragmatic systems required
- Same or similar collection systems in all Member States
- Discussion on unsolved species differentiation
- Consultation with stakeholders on interpretation of data
- Joint effort industry / regulators essential

## **Key principles**



- As introduced in the HMA/EMEA Meeting May 2009
  - Importance of contextual data
  - National, Harmonized collection of data
  - Industry can supply the most accurate data at a National level
  - Simple and robust system
  - Species split
  - Confidentiality rules
  - All marketers must be obliged to supply data does the legal base exist for this?
  - IFAH-Europe supports pragmatic volume data collection

IFAH paper Antibiotic Volumes and Context Septembre 2009

## Why do we collect usage data?



- General framework of Risk Analysis
  - Risk profile
  - Risk assessment
    - Hazard identification
    - Hazard characterization
  - Risk management
    - Measure the impact of risk management options
  - Risk communication
    - Transparency

#### How to collect data?



- Report from industry to national country authorities
  - Weight or presentations sold
  - By license number
  - All manufacturers
- Species split
  - Industry is open to harmonization with PSUR data

## How to report data?



- Reporting of data by antimicrobial classes according to current third level of ATC vet code (e.g. Danmap)
- Oral / Parenteral / Intramammary / External
- Confidentiality of data at country / regional level
  - Some classes have too few compounds to be presented independently
- Importance of data formatting for potential risk assessment
  - Measuring exposure at animal level is essential

#### ATCvet code / DDD



- Complexity
  - Numerous species, different weights
  - Compilation of data difficult
- Dosing / Posology not harmonized in Europe
  - Does not automatically reflect prescribed dose or used dose
- Few countries have adopted that approach yet
- Fitness for purpose ?

#### Feed additives



- Ionophores explicitly out of WHO list
- Different legal status in Europe
- Not collected in every country as of today
- Not essential at this stage

#### **Conclusions**



- Simple and robust
- All data to be collected
- Importance of contextual data
- Simple species split
- Need of Fitness for risk assessment

## **Backup slides**





## **Proposed reporting**



- Tetracyclins
- Amphenicols
- Penicillins
- Cephalosporins
- Trimethoprim / Sulfonamides
- Macrolides / Lincosamides
- Aminoglycosides
- Polypeptids
- Fluoroquinolones
- Quinolones
- Pleuromutilins
- Proposal without prejudice to any national or regional confidentiality issue that may affect reporting
- Classes used only in companion animals need to be taken into account again with due respect to confidentiality issues